Stay updated with breaking news from Nasdaq nbix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective cut by JPMorgan Chase & Co. from $154.00 to $148.00 in a report published on Friday, Benzinga reports. They currently have an overweight rating on the stock. Several other research analysts have also weighed in on the stock. Raymond James upped their price objective on […] ....
WINTON GROUP Ltd grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 68.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,272 shares of the company’s stock after acquiring an additional 1,738 shares during the period. WINTON GROUP Ltd’s […] ....
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) insider Eiry Roberts sold 1,114 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $132.96, for a total value of $148,117.44. Following the completion of the sale, the insider now owns 23,716 shares in the company, […] ....
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) – Investment analysts at William Blair dropped their Q1 2024 EPS estimates for Neurocrine Biosciences in a report released on Wednesday, February 7th. William Blair analyst M. Minter now expects that the company will earn $1.04 per share for the quarter, down from their prior estimate of $1.19. […] ....
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) – Investment analysts at Cantor Fitzgerald upped their FY2024 earnings per share estimates for shares of Neurocrine Biosciences in a research report issued on Thursday, February 8th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will post earnings per share of $5.05 for the year, up […] ....